This page shows the latest Alzheimer news and features for those working in and with pharma, biotech and healthcare.
Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval. ... UK, the Alzheimer’s Society and the National Institute of Health and Care Research.
Alzheimer’s Research UK, the Alzheimer’s Society and the National Institute of Health and Care Research have announced a £5m-funded project to make blood tests for Alzheimer’s disease ... The Alzheimer’s Research UK’s 2023 Dementia Attitudes
The FDA’s decision on AVB-101 comes shortly after the Alzheimer's Society raised concerns that not enough people are being diagnosed with young-onset dementia in England. ... A report from NHS England revealed that 34, 412 people in England have been
Alzheimer’s Research UK has published the results of a nationwide survey of public perceptions of dementia in its Dementia Attitudes Monitor. ... Samantha Benham-Hermetz, executive director of policy and communications at Alzheimer’s Research UK,
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Clinical Trials on ... tasks. Eisai also presented an analysis of a small subgroup of patients
James White, head of national influencing at Alzheimer’s Society, highlighted the importance of quashing the “common misconception” that dementia is a condition for older people. ... Alzheimer’s Society urges more people to know the symptoms of
More from news
Approximately 219 fully matching, plus 436 partially matching documents found.
To illustrate the point, let’s look at the example of Alzheimer’s disease (AD).
This year, the 17th World Congress on Controversies in Neurology (CONy) took place in Dubrovnik, Croatia and focused on genetic, biomedical, pathological and technological pathways of diseases like Alzheimer’s to
A look through the calendar for the next few months shows delegates coming together for conditions ranging from Alzheimer’s through to cardiology and urology, and journeying from Amsterdam to Vancouver
Alzheimer’s disease, schizophrenia and other neurological and psychiatric disorders.
By Charlotte Maule. With the potential approval of the first disease-modifying treatment (DMT) for Alzheimer’s disease (AD) on the horizon – and further treatment candidates in development – stakeholders need to ... Organization. Diagnosis of
More from intelligence
Approximately 10 fully matching, plus 47 partially matching documents found.
With fifteen years’ experience of working with government, parliament and healthcare charities – including Cancer Research UK, Diabetes UK and the Alzheimer's Society – Butterworth has a proven track record in senior
She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.
Alzheimer's disease.
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease. ... Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures.” Journal of Alzheimer’s Disease.
Eryn chose to run on behalf of Alzheimer's Society in memory of her grandad, who passed away in 2007. ... In preparation for her run, Eryn said Alzheimer's Society was hugely supportive.
Common signs of Alzheimer's disease include difficulties with:. Remembering recent conversations or events. ... It is the second most common type of dementia after Alzheimer's disease.
The RISE study includes a research registry created to help ensure the LGBTQIA+ community is represented in Alzheimer’s research.
Alzheimer’s disease).
More from PMHub
Approximately 4 fully matching, plus 26 partially matching documents found.
No results were found
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...